Wednesday, May 10, 2023 2:57:07 PM
"Item 1.01
Entry into a Material Definitive Agreement.
On May 4, 2023 (the “Effective Date”), the Company and Cilandro SA, (Cilandro) entered into a Sales Purchase agreement, to acquire 100% of the share capital of Cilandro in a share swap transaction representing all the assets, licenses , and intellectual property of.
Pursuant to the provisions in the Sale Purchase Agreement, the Company will issue (one hundred and ten thousand) 110,000 shares of its common stock at fair market value as of the date of the Sale Purchase Agreement. In addition, the Company will issue a 10% convertible note for (Fifty Eight Thousand Dollars) $58,000 with a maturity date of December 31, 2023. The convertible note has an option to convert into the Company’s common stock with a conversion price of (One Dollar) $1.0000.The common shares issued for the conversion if exercised, shall be issued with a restriction under Rule 144 of the U.S. Securities and Exchange Commission Act of 1934.
The completion of the sale must be reported and approved by SOFIT a self-regulatory AML (Anti Money Laundering) regulatory body authorized by FINMA (Swiss Financial Market Supervisory Authority) in Switzerland. The seller will remain as a Director of Cilandro and have operational oversight on an ongoing basis. The Company shall commit to providing Directors and Officers insurance for Cilandro.
The Company shall recruit executives to manage the business and administrative activities of Cilandro. These individuals shall each enter into an employment agreement for executive-level roles with the subsidiary company for a term of not less than two years and receive reasonable compensation packages to include a competitive base salary..."
Recent ARAT News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:39:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:34:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 08:53:35 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 01/30/2024 10:01:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 04:13:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 02:31:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 01:48:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 02:30:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/27/2023 07:27:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/22/2023 08:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 02:44:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 12:00:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/16/2023 01:38:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM